[go: up one dir, main page]

DE602005027820D1 - Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien - Google Patents

Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien

Info

Publication number
DE602005027820D1
DE602005027820D1 DE602005027820T DE602005027820T DE602005027820D1 DE 602005027820 D1 DE602005027820 D1 DE 602005027820D1 DE 602005027820 T DE602005027820 T DE 602005027820T DE 602005027820 T DE602005027820 T DE 602005027820T DE 602005027820 D1 DE602005027820 D1 DE 602005027820D1
Authority
DE
Germany
Prior art keywords
expression cassettes
promoter expression
rnai agents
simultaneous introduction
multiple promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005027820T
Other languages
English (en)
Inventor
Petrus W Roelvink
David A Suhy
Alexander A Kolykhalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benitec Inc
Original Assignee
Benitec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Inc filed Critical Benitec Inc
Publication of DE602005027820D1 publication Critical patent/DE602005027820D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602005027820T 2004-03-05 2005-03-04 Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien Expired - Lifetime DE602005027820D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55050404P 2004-03-05 2004-03-05
US55392004P 2004-03-17 2004-03-17
PCT/US2005/007447 WO2005087926A2 (en) 2004-03-05 2005-03-04 Multiple promoter expression cassettes for simultaneous delivery of rnai agents

Publications (1)

Publication Number Publication Date
DE602005027820D1 true DE602005027820D1 (de) 2011-06-16

Family

ID=34963938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027820T Expired - Lifetime DE602005027820D1 (de) 2004-03-05 2005-03-04 Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien

Country Status (13)

Country Link
US (3) US7727970B2 (de)
EP (2) EP1725660B1 (de)
JP (1) JP4763681B2 (de)
KR (2) KR101337579B1 (de)
CN (1) CN103060324B (de)
AT (1) ATE508190T1 (de)
AU (1) AU2005222084B2 (de)
CA (1) CA2558771C (de)
DE (1) DE602005027820D1 (de)
DK (1) DK1725660T3 (de)
IL (1) IL177862A (de)
NZ (1) NZ550284A (de)
WO (1) WO2005087926A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550284A (en) * 2004-03-05 2009-04-30 Benitec Ltd Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
CA2824308A1 (en) 2004-09-24 2006-04-06 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by rnai
CA2587854C (en) * 2004-11-18 2014-01-21 The Board Of Trustees Of The University Of Illinois Multicistronic sirna constructs to inhibit tumors
US8076471B2 (en) 2005-02-03 2011-12-13 Benitec, Inc. RNAi expression constructs
WO2006116756A1 (en) * 2005-04-28 2006-11-02 Benitec, Limited. Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
US7452696B2 (en) * 2006-10-27 2008-11-18 National Taiwan University Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo
WO2008069940A2 (en) * 2006-12-06 2008-06-12 Albert Einstein College Of Medicine Of Yeshiva University Multi-microrna methods and compositions
WO2008134720A2 (en) * 2007-04-30 2008-11-06 Medtronic, Inc. Inert dna sequences for efficient viral packaging and methods of use
US8614198B2 (en) * 2007-06-22 2013-12-24 Alnylam Pharmaceuticals, Inc. Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US20100041133A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
CA2833908C (en) 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CA3050894C (en) * 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
EP2633051B1 (de) 2010-10-28 2016-09-14 Benitec Biopharma Limited Hbv-behandlung
KR101554678B1 (ko) * 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
RU2015133252A (ru) 2013-01-08 2017-02-10 Бенитек Байофарма Лимитед Лечение возрастной макулярной дегенерации
ES2856403T3 (es) 2014-03-18 2021-09-27 Univ Massachusetts Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
EP3795580A1 (de) 2014-10-03 2021-03-24 University of Massachusetts Hocheffiziente bibliotheksidentifizierte aav-vektoren
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
HK1244299A1 (zh) 2014-11-14 2018-08-03 Voyager Therapeutics, Inc. 治療肌萎縮側索硬化(als)的組合物和方法
WO2016081808A1 (en) 2014-11-20 2016-05-26 The Regents Of The University Of California Compositions and methods related to hematologic recovery
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
EP3364996B1 (de) 2015-10-22 2021-08-25 University of Massachusetts Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
WO2017176929A1 (en) 2016-04-05 2017-10-12 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
WO2018017814A1 (en) 2016-07-20 2018-01-25 President And Fellows Of Harvard College Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
WO2018053142A2 (en) 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (ko) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
US20190314427A1 (en) 2016-12-16 2019-10-17 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
WO2018136617A2 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
EP3618839A4 (de) * 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
WO2018208972A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
WO2019046401A1 (en) 2017-08-29 2019-03-07 Evelo Biosciences, Inc. TREATMENT OF CANCER USING BLAUTIA STRAIN
JP7397488B2 (ja) 2017-09-22 2023-12-13 ユニバーシティ オブ マサチューセッツ Ｓｏｄ１二重発現ベクターおよびその使用
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
WO2019169138A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using paraclostridium benzoelyticum
WO2019169143A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using turicibacter sanguinis
WO2019169160A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using ruminococcus gnavus
WO2019169168A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using agathobaculum
WO2019178057A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Methods of treating cancer using burkholderia
US20210047645A1 (en) * 2018-05-08 2021-02-18 Mayo Foundation For Medical Education And Research Methods for treating ovarian cancer
EP3802829A4 (de) 2018-06-08 2022-10-19 University of Massachusetts Antisense-oligonukleotide zur wiederherstellung der dysferlinproteinexpression bei zellen von patienten mit dysferlinopathie
WO2020172229A1 (en) * 2019-02-19 2020-08-27 Board Of Regents, The University Of Texas System Genetic targeting of cellular or neuronal sub-populations
BR112021017864A2 (pt) 2019-03-12 2021-12-07 Harvard College Métodos e composições para tratamento do câncer
JP2022527629A (ja) 2019-04-05 2022-06-02 アーリー・インコーポレイテッド 合成バイオマーカーのための改良された方法及び組成物
WO2020252257A1 (en) 2019-06-12 2020-12-17 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
EP4088742A4 (de) 2020-01-06 2024-07-10 Seasun Therapeutics Zusammensetzung zum vorbeugen oder behandeln von makuladegeneration, die einen zelldurchlässigen nukleinsäurekomplex als wirkstoff enthält
WO2021178556A1 (en) 2020-03-04 2021-09-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
EP4157264A4 (de) 2020-05-27 2024-06-19 The Regents of the University of California Zusammensetzungen und verfahren zur transdifferenzierung von zellen
WO2022056454A2 (en) 2020-09-14 2022-03-17 President And Fellows Of Harvard College Methods and compositions for treating hpv-positive cancers
AU2021344422A1 (en) 2020-09-16 2023-05-04 Gordon J. Freeman Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
US20250230412A1 (en) 2022-02-01 2025-07-17 President And Fellows Of Harvard College Methods and compositions for treating cancer
CN119137278A (zh) * 2022-03-24 2024-12-13 细胞和大脑有限公司 新型重组载体及其用途
WO2023182870A1 (ko) * 2022-03-24 2023-09-28 (주)셀레브레인 신규 재조합 벡터 및 이의 용도
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
PL169273B1 (pl) 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
AU743316C (en) * 1998-03-20 2005-09-15 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
AU2001254563A1 (en) 2000-04-21 2001-11-12 Boehringer Ingelheim (Canada) Ltd. Internal de novo initiation sites of the hcv ns5b polymerase and use thereof
US6693701B2 (en) * 2001-05-29 2004-02-17 Ibsen Photonics A/S Method and apparatus for diffractive transfer of a mask grating
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
WO2003016572A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Oligonucleotide therapeutics for treating hepatitis c virus infections
US7732193B2 (en) 2001-09-13 2010-06-08 California Institute Of Technology Method for expression of small RNA molecules within a cell
WO2003046186A1 (en) * 2001-11-28 2003-06-05 Toudai Tlo, Ltd. siRNA EXPRESSION SYSTEM AND METHOD FOR PRODUCING FUNCTIONAL GENE KNOCK-DOWN CELLS USING THE SYSTEM
EP1430157B1 (de) * 2002-02-20 2011-08-10 Sirna Therapeutics, Inc. Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
CA2478910C (en) * 2002-03-14 2012-08-21 Commonwealth Scientific And Industrial Research Organisation Methods and means for monitoring and modulating gene silencing
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
US20040053876A1 (en) 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US8211455B2 (en) * 2002-06-19 2012-07-03 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
ATE427352T1 (de) * 2002-07-26 2009-04-15 Novartis Vaccines & Diagnostic Modifizierte kleine irns molekule und methoden zu deren anwendung
EP1572943B1 (de) 2002-08-29 2015-04-22 The Board of Trustees of The Leland S. Stanford Junior University Zirkuläre nukleinsäurevektoren sowie verfahren zur herstellung und verwendung davon
EP1591524A4 (de) * 2003-01-24 2007-12-26 Tokyo Metropolitan Org Med Res Oligoribonukleotid oder peptidische nukleinsäure, das bzw. die die funktion des hepatitis-c-virus hemmt
CN1276976C (zh) 2003-10-30 2006-09-27 封江南 单一载体编码多个发夹结构小干扰性rna表达系统及其构建方法
ES2366126T3 (es) * 2004-03-05 2011-10-17 Benitec, Inc. CASSETTE DE EXPRESIÓN DE PROMOTOR MÚLTIPLE PARA EL SUMINISTRO SIMULTÁNEO DE AGENTES ARNi.
NZ550284A (en) 2004-03-05 2009-04-30 Benitec Ltd Multiple promoter expression cassettes for simultaneous delivery of RNAi agents

Also Published As

Publication number Publication date
JP4763681B2 (ja) 2011-08-31
KR101337579B1 (ko) 2013-12-06
JP2007527244A (ja) 2007-09-27
CN103060324A (zh) 2013-04-24
NZ550284A (en) 2009-04-30
CA2558771C (en) 2013-01-08
AU2005222084A1 (en) 2005-09-22
WO2005087926A2 (en) 2005-09-22
US20130171726A1 (en) 2013-07-04
EP1725660B1 (de) 2011-05-04
IL177862A0 (en) 2006-12-31
WO2005087926A3 (en) 2006-03-16
US8691967B2 (en) 2014-04-08
EP2363483A2 (de) 2011-09-07
US8283461B2 (en) 2012-10-09
EP2363483A3 (de) 2014-07-16
KR101246862B1 (ko) 2013-03-27
ATE508190T1 (de) 2011-05-15
CN103060324B (zh) 2015-04-01
US7727970B2 (en) 2010-06-01
CA2558771A1 (en) 2005-09-22
AU2005222084B2 (en) 2010-04-22
US20110003378A1 (en) 2011-01-06
DK1725660T3 (da) 2011-08-29
US20050197313A1 (en) 2005-09-08
KR20120008094A (ko) 2012-01-25
KR20070063470A (ko) 2007-06-19
EP1725660A2 (de) 2006-11-29
IL177862A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
DE602005027820D1 (de) Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1115786T1 (el) Μεσο φυλαξης για κυτταρα
EP2061907A4 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
CY1116482T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
NO20071127L (no) Triazoloftalaziner
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
HRP20150828T8 (hr) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
CY1119509T1 (el) Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης
ECSP077360A (es) Compuestos sulfonamida
EP2195331A4 (de) Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE528381T1 (de) Verwendung von carboxylsäureestern als duftstoff
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
ATE553123T1 (de) Wachstumsfaktormutanten mit hoher aktivität
EA201071031A1 (ru) Носители никорандила с повышенной стабильностью
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
DOP2007000020A (es) Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
EA200801385A1 (ru) Способ образования дендритных клеток с применением пониженной температуры
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität